CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong · Delayed Price · Currency is HKD 8.63
+0.01 (0.12%)
Jul 25, 2025, 4:08 PM HKT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Vitamin C | 1.99B | Log In | Log In | Log In | Log In | Upgrade |
Vitamin C Growth | 13.46% | Log In | Log In | Log In | Log In | Upgrade |
Antibiotics | 1.59B | Log In | Log In | Log In | Log In | Upgrade |
Antibiotics Growth | -5.40% | Log In | Log In | Log In | Log In | Upgrade |
Functional Food and Others | 1.69B | Log In | Log In | Log In | Log In | Upgrade |
Functional Food and Others Growth | -19.38% | Log In | Log In | Log In | Log In | Upgrade |
Nervous System | 9.65B | Log In | Log In | Log In | Log In | Upgrade |
Nervous System Growth | -8.53% | Log In | Log In | Log In | Log In | Upgrade |
Oncology | 4.40B | Log In | Log In | Log In | Log In | Upgrade |
Oncology Growth | -47.02% | Log In | Log In | Log In | Log In | Upgrade |
Anti-Infectives | 4.09B | Log In | Log In | Log In | Log In | Upgrade |
Anti-Infectives Growth | -16.04% | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular | 2.08B | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular Growth | -31.16% | Log In | Log In | Log In | Log In | Upgrade |
Respiratory System | 1.20B | Log In | Log In | Log In | Log In | Upgrade |
Respiratory System Growth | -30.84% | Log In | Log In | Log In | Log In | Upgrade |
Digestion and Metabolism | 1.05B | Log In | Log In | Log In | Log In | Upgrade |
Digestion and Metabolism Growth | 2.89% | Log In | Log In | Log In | Log In | Upgrade |
Other Therapeutic Areas | 1.26B | Log In | Log In | Log In | Log In | Upgrade |
Other Therapeutic Areas Growth | -7.90% | Log In | Log In | Log In | Log In | Upgrade |
Licence Fee Income | 17.83M | Log In | Log In | Log In | Log In | Upgrade |
Licence Fee Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Finished Drugs Segment Profit | 4.83B | Log In | Log In | Log In | Log In | Upgrade |
Finished Drugs Segment Profit Growth | -37.73% | Log In | Log In | Log In | Log In | Upgrade |
Vitamin C Segment Profit | 211.28M | Log In | Log In | Log In | Log In | Upgrade |
Vitamin C Segment Profit Growth | -2239.19% | Log In | Log In | Log In | Log In | Upgrade |
Antibiotics Segment Profit | 299.18M | Log In | Log In | Log In | Log In | Upgrade |
Antibiotics Segment Profit Growth | 21.54% | Log In | Log In | Log In | Log In | Upgrade |
Functional Food and Others Segment Profit | 305.29M | Log In | Log In | Log In | Log In | Upgrade |
Functional Food and Others Segment Profit Growth | -50.72% | Log In | Log In | Log In | Log In | Upgrade |
Other | -277.18M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -22.19% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Mainland China | 25.11B | Log In | Log In | Log In | Log In | Upgrade |
Mainland China Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Asian Regions | 1.18B | Log In | Log In | Log In | Log In | Upgrade |
Other Asian Regions Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Americas | - | Log In | Log In | Log In | Log In | Upgrade |
Americas Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Europe | 1.31B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
North America | 853.04M | Log In | Log In | Log In | Log In | Upgrade |
North America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies | 553.88M | Log In | Log In | Log In | Log In | Upgrade |
Other Geographies Growth | - | Log In | Log In | Log In | Log In | Upgrade |